Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

The literature on colorectal cancer is certainly still unclear ... the FLEX trial before committing to the widespread use of cetuximab in patients with NSCLC.boxed-text Addition of cetuximab ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...

Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the ...

Cetuximab has clearly increased the therapeutic armamentarium for the treatment of patients with mCRC. Studies looking at clinical, biochemical, and molecular markers for increased activity have ...

The currently approved administration schedule for cetuximab is the weekly schedule (400 mg/m 2 initial dose followed by 250 mg/m 2 weekly); however, the commonly used chemotherapy agents for CRC ...

in combination with cetuximab for previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer. With a median follow-up of 11.9 months in 94 patients, Krazati plus ...